Apimeds, Inc.
🇰🇷South Korea
Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Phase 2
1 (33.3%)Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients
Phase 3
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Apitox - pure honeybee toxinDrug: Placebo
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Apimeds, Inc.
- Target Recruit Count
- 468
- Registration Number
- NCT03710655
Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Apimeds, Inc.
- Target Recruit Count
- 363
- Registration Number
- NCT01112722
- Locations
- 🇺🇸
Functional Research LLC, Gulf Shores, Alabama, United States
🇺🇸Tucson Orthopaedic Institute, Tucson, Arizona, United States
🇺🇸SC Clinical Research Inc., Upland, California, United States
Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation
Phase 2
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: honeybee venom (Apitoxin (Korea) Apitox (USA))
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2010-05-05
- Lead Sponsor
- Apimeds, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00949754
- Locations
- 🇺🇸
Radiant Research Inc., Pinellas Park, Florida, United States
🇺🇸Radiant Research - Chicago, Chicago, Illinois, United States
🇺🇸Radiant Research - Columbus, Columbus, Ohio, United States
News
No news found